[{"from": "human", "value": "What can you tell me about this molecule? [C][C][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][=C][C][=Branch2][Ring2][S][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][=C][C][=Branch1][=Branch1][=N][C][=N][Ring1][=Branch1][N][Branch1][C][C][C][=Branch1][C][=O][N][C][=C][Branch1][S][C][=Branch1][O][=C][C][=Branch1][Branch1][=C][Ring1][=Branch1][Cl][O][C][O][C][Cl][N][C][=Branch1][C][=O][C][=C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, H3B-6527 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. FGFR4, a receptor tyrosine kinase overexpressed by certain tumor cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival; FGFR4 expression is associated with poor prognosis."}]